Forum

Veterinary Biologics Market Overview

The global Veterinary Biologics Market is expanding as livestock producers, veterinarians, and pet owners increasingly prioritize disease prevention and advanced animal healthcare. Veterinary biologics include vaccines, monoclonal antibodies, antisera, immunomodulators, and other biological products used to prevent or treat diseases in livestock and companion animals. According to the Veterinary Biologics Market report by IG Transformation Partners, the global market was valued at USD 14.2 billion in 2025 and is projected to reach USD 25.7 billion by 2034.

The market is expected to grow at a CAGR of 6.8% during 2026-2034. Increasing incidence of zoonotic and transboundary animal diseases, rising pet ownership, stricter food safety requirements, and growing adoption of preventive vaccination are supporting market growth. North America held the largest regional share in 2025, while Asia-Pacific is projected to be the fastest-growing region during the forecast period.

Explore the market scope, research coverage, and key industry insights through the sample report. Download the Free Sample Report

Market Size and Growth Outlook

The Veterinary Biologics Market is evolving from conventional vaccines toward advanced biological products designed for more targeted and longer-lasting protection. Recombinant vector, subunit, and RNA-particle vaccine technologies are gaining attention because they can help manufacturers respond to emerging pathogen strains. Monoclonal antibodies are also extending the role of biologics beyond preventive vaccination into the treatment of chronic conditions in companion animals.

Livestock health remains a major source of demand. Cattle, poultry, and swine producers depend on vaccination programs to reduce disease-related losses, protect productivity, and meet animal health requirements in domestic and export markets. At the same time, increased spending on companion animal healthcare is supporting demand for specialized vaccines and antibody therapies.

Market Snapshot

Source: IG Transformation Partners.

Access the complete market assessment, including product segmentation, animal type analysis, regional forecasts, and competitive developments. Explore the Full Veterinary Biologics Market Report

Key Drivers of the Veterinary Biologics Market

1. Rising Incidence of Zoonotic and Transboundary Animal Diseases

Animal diseases such as foot-and-mouth disease, African swine fever, highly pathogenic avian influenza, and peste des petits ruminants can cause significant livestock losses and disrupt international trade. Outbreaks may lead to movement restrictions, trade barriers, and additional biosecurity requirements.

Vaccination is an important preventive measure for many animal diseases. Governments, livestock producers, and veterinary organizations therefore invest in immunization programs to protect animal populations and reduce the economic impact of outbreaks.

Zoonotic diseases also create public health concerns because infections such as rabies and brucellosis can spread from animals to humans. This strengthens the importance of coordinated animal vaccination and disease surveillance programs.

2. Growing Focus on Preventive Animal Healthcare

Livestock producers are increasingly emphasizing prevention rather than relying only on treatment after a disease outbreak. Vaccination programs can help reduce animal mortality, improve herd health, and support consistent agricultural production.

Food safety requirements and antimicrobial stewardship policies are also encouraging preventive approaches. Veterinary biologics can help reduce the need for certain antibiotic treatments by preventing infections before they spread through animal populations.

3. Expansion of Pet Ownership and Veterinary Spending

Growing pet ownership and the increasing humanization of companion animals are supporting demand for advanced veterinary healthcare. Pet owners are showing greater interest in preventive care, routine vaccinations, and treatments for chronic conditions.

Dogs and cats are important markets for newer biological therapies. Veterinary clinics are expanding their service offerings to include specialized injectable treatments, vaccination reminders, and wellness programs. These developments support recurring demand for biologics.

4. Increasing Livestock Production

Expanding dairy, poultry, beef, and pork production is creating a larger market for animal vaccines and other biological products. Commercial farms require structured vaccination programs to maintain animal health and reduce production disruptions.

Large-scale livestock operations also need reliable vaccine supply, cold-chain distribution, and veterinary oversight. These requirements create opportunities for manufacturers with established distribution networks and production capabilities.

5. Government Vaccination and Animal Health Programs

National animal health initiatives are supporting demand for veterinary biologics. Government vaccination programs targeting diseases such as foot-and-mouth disease and brucellosis can create significant recurring demand.

Regulatory frameworks also influence product development and market access. Veterinary biologics manufacturers must meet licensing, quality, and safety requirements before products can be marketed in different countries.

Key Trends Transforming the Industry

Platform-Based and RNA-Particle Vaccine Technologies

Platform-based vaccine development is emerging as an important industry trend. Instead of developing an entirely new manufacturing process for each pathogen, platform technologies can use an established production process while changing the antigen to address a specific strain.

Recombinant vector, subunit, and nucleic acid-based technologies are attracting attention across livestock and companion animal applications. These approaches may support faster development and help manufacturers respond to emerging disease threats.

An example is Merck Animal Health's Nobivac NXT Canine Flu H3N2, which received USDA approval in June 2024 and was described by the company as its first canine influenza vaccine built on an RNA-particle platform.

Growth of Monoclonal Antibody Therapies

Monoclonal antibodies are expanding the role of veterinary biologics from disease prevention into targeted treatment. These therapies can be developed to address specific biological targets associated with pain, inflammation, allergies, and infectious diseases.

Longer-acting formulations are particularly relevant to companion animal care because they can reduce the frequency of medication administration. This can improve treatment convenience for pet owners and create additional service opportunities for veterinary clinics.

Personalized and Herd-Specific Vaccination

Disease conditions and circulating pathogen strains can vary between farms and regions. This is encouraging interest in herd-specific vaccination strategies supported by veterinary diagnostics and pathogen sequencing.

By understanding the disease profile of a particular herd, veterinarians and manufacturers can better evaluate suitable vaccine approaches. Integration between diagnostics and vaccine development may become increasingly important for livestock disease management.

Automation in Poultry Vaccination

The use of in-ovo vaccination is increasing as commercial hatcheries seek efficient ways to immunize poultry. This approach delivers vaccines to embryos before chicks hatch, supporting early protection and consistent dosing.

Automated hatchery equipment can reduce the need to handle individual chicks and help large poultry producers manage vaccination at scale. These advantages are supporting interest in in-ovo delivery systems.

Veterinary Biologics Market Segmentation Analysis

The market is segmented by product type, animal type, route of administration, and end user.

By Product Type

• Vaccines: This segment held the largest market share in 2025. Vaccines are widely used across cattle, poultry, swine, dogs, and cats. Routine immunization programs and government vaccination campaigns support recurring demand.

• Monoclonal Antibodies: This segment is projected to register the fastest CAGR as targeted therapies for pain, allergies, and infectious diseases gain adoption in companion animal healthcare.

• Antisera: Antisera are used in selected veterinary applications requiring specific antibody-based interventions.

• Immunomodulators: These products support the regulation of immune responses in veterinary healthcare.

• Others: This category includes additional biological products used in animal health.

By Animal Type

• Cattle: This segment held the largest market share in 2025. Demand is supported by large dairy and beef populations and vaccination programs targeting respiratory, reproductive, and infectious diseases.

• Dogs: This segment is projected to grow at the fastest CAGR, supported by increasing pet healthcare expenditure and the introduction of specialized antibody therapies.

• Poultry: Vaccination programs are important for commercial poultry operations, particularly in disease prevention and flock health management.

• Swine: Biologics help producers manage infectious disease risks and protect herd productivity.

• Cats: Growing companion animal healthcare spending supports demand for feline vaccines and other biological products.

• Others: This category includes additional animal species.

By Route of Administration

• Injectable: This segment held the largest market share in 2025 because injections are widely used for vaccines, monoclonal antibodies, and antisera.

• In-Ovo: This segment is projected to register the fastest CAGR as commercial poultry producers adopt automated hatchery vaccination systems.

• Oral: Oral biologics offer an alternative administration route for selected veterinary products.

• Intranasal: Intranasal products are used for certain vaccines and respiratory disease prevention applications.

• Others: Other routes cover additional administration methods.

By End User

• Livestock Farms: This segment held the largest market share in 2025. Commercial cattle, poultry, and swine operations purchase biologics in large volumes to support routine vaccination and herd health programs.

• Veterinary Clinics: This segment is projected to grow at the fastest CAGR, supported by increasing use of companion animal vaccines and injectable antibody therapies.

• Veterinary Hospitals: Hospitals provide specialized treatment and biological therapies for animals requiring advanced care.

• Research Institutes: These organizations support veterinary vaccine development, testing, and disease research.

• Others: Other end users include additional animal health organizations.

Regional Analysis of the Veterinary Biologics Market

North America

North America held the largest market share in 2025, accounting for 40% of global revenue. The United States represents the largest country market in the region, supported by a substantial livestock and companion animal base, established veterinary healthcare infrastructure, and a mature regulatory system.

Canada contributes through its livestock sector and veterinary biologics oversight, while Mexico adds demand from commercial poultry and swine production. High veterinary spending and the adoption of advanced companion animal therapies also support regional growth.

Asia-Pacific

Asia-Pacific is projected to be the fastest-growing regional market during the forecast period. Expanding livestock production, increasing pet ownership, and government animal health programs are supporting demand.

China represents the largest country market in the region, while India is projected to be the fastest-growing country market. Rising dairy and poultry production, vaccination initiatives, and investment in domestic manufacturing are creating opportunities for biologics suppliers.

Europe

Europe represents an established market supported by animal health regulations, veterinary infrastructure, and demand for livestock and companion animal healthcare. Germany is the largest country market in the region, with France, the United Kingdom, and Italy also contributing to market activity.

Regulatory harmonization under the European Union's veterinary medicinal products framework influences product authorization and market access across member states.

Latin America

Brazil represents the largest country market in Latin America, while Chile is projected to be the fastest-growing country market. Commercial livestock production and disease prevention requirements support demand for vaccines and other veterinary biologics.

Middle East and Africa

Saudi Arabia is the largest country market in the Middle East and Africa region, while the United Arab Emirates is projected to be the fastest-growing country market. Livestock health programs and investment in animal healthcare infrastructure support market opportunities.

Competitive Landscape and Key Companies

The Veterinary Biologics Market includes global animal health companies and regional manufacturers competing across livestock and companion animal applications. Competition is influenced by product quality, regulatory approvals, manufacturing capabilities, cold-chain distribution, and relationships with veterinarians and livestock producers.

Leading companies are investing in monoclonal antibody development, advanced vaccine platforms, and manufacturing expansion. Partnerships and regional licensing arrangements also help companies enter new markets and expand product availability.

Key companies identified in the market include:

• Zoetis Inc.

• Merck Animal Health

• Boehringer Ingelheim

• Elanco Animal Health

• Ceva Santé Animale

• HIPRA

• Virbac

• Biogénesis Bagó

• Phibro Animal Health Corporation

• Indian Immunologicals Limited

• Medgene

• ImmuCell Corporation

• Hester Biosciences Limited

• Huvepharma

• Kyoritsu Seiyaku Corporation

Recent Industry Developments

Recent developments highlight the growing importance of monoclonal antibodies and next-generation animal vaccines.

• October 2025: Zoetis received Health Canada approval for Lenivia, an injectable monoclonal antibody for alleviating osteoarthritis pain in dogs. The company described it as a long-acting treatment providing up to three months of pain relief with one injection.

• December 2025: Elanco received USDA approval for Befrena, a monoclonal antibody injection for canine allergic and atopic dermatitis. The company began a phased US launch in May 2026.

• July 2026: Medgene introduced a prescription platform vaccine in the United States targeting Theileria orientalis Ikeda in cattle.

• September 2026: The Bureau of Animal Industry in the Philippines approved commercial sale of AVAC ASF LIVE, an African swine fever vaccine developed by AVAC Vietnam, for fattening pigs.

These developments reflect investment in targeted therapies, platform vaccine technologies, and solutions for livestock disease management.

Opportunities and Challenges in the Market

Key Growth Opportunities

Monoclonal Antibody Development: Targeted therapies for chronic pain, allergies, and infectious diseases offer opportunities to expand biologics use in companion animal healthcare.

Emerging Vaccine Platforms: Recombinant, subunit, and RNA-particle technologies can help manufacturers develop products for emerging and changing pathogen strains.

Expanding Asian Livestock Markets: Growing cattle, poultry, and swine production in Asia-Pacific creates opportunities for vaccine manufacturers and regional distributors.

Automated Vaccination Systems: In-ovo administration and automated hatchery equipment can improve vaccination efficiency in large-scale poultry operations.

Key Market Challenges

Regulatory Complexity: Veterinary biologics require product-specific approvals and compliance with national quality and safety standards. Different regulatory requirements can increase market-entry costs.

Cold-Chain Requirements: Many biological products require controlled storage and transportation conditions. Maintaining product quality across long distribution networks can be challenging.

Manufacturing Costs: Advanced biologics and monoclonal antibodies require specialized production processes, quality controls, and investment in manufacturing infrastructure.

Disease Variability: Differences in circulating strains and regional disease patterns can complicate vaccine development and vaccination planning.

Future Outlook of the Veterinary Biologics Market

The future of the Veterinary Biologics Market will be shaped by advanced vaccine platforms, monoclonal antibody therapies, growing livestock production, and increasing investment in companion animal healthcare. Preventive vaccination is expected to remain central to animal disease management, while targeted biological treatments may expand the market beyond conventional immunization.

Asia-Pacific is positioned to offer significant growth opportunities as livestock production and pet ownership increase. Meanwhile, established markets in North America and Europe are expected to remain important for advanced biologics and specialized veterinary treatments.

With the global market projected to reach USD 25.7 billion by 2034 at a CAGR of 6.8%, opportunities are emerging across vaccines, antibody therapies, manufacturing, and veterinary distribution. Companies that combine scientific innovation with regulatory expertise and reliable supply chains will be well positioned to participate in this evolving market.

Frequently Asked Questions (FAQs)

1. What is the Veterinary Biologics Market?

The Veterinary Biologics Market includes vaccines, monoclonal antibodies, antisera, immunomodulators, and other biological products used to prevent or treat diseases in livestock and companion animals.

2. What is the global Veterinary Biologics Market size?

The global market was valued at USD 14.2 billion in 2025 and is projected to reach USD 25.7 billion by 2034.

3. What is the projected CAGR of the market?

The market is expected to grow at a CAGR of 6.8% during the 2026-2034 forecast period.

4. Which region dominates the Veterinary Biologics Market?

North America held the largest market share in 2025, accounting for 40% of global revenue.

5. Which region is expected to grow fastest?

Asia-Pacific is projected to be the fastest-growing region, supported by expanding livestock production, rising pet ownership, and government animal health programs.

6. Which product type holds the largest market share?

Vaccines held the largest market share in 2025 because of their widespread use in livestock and companion animal disease prevention.

7. Which product type is expected to grow fastest?

Monoclonal antibodies are projected to register the fastest CAGR as targeted treatments for pain, allergies, and infectious diseases gain adoption.

8. Which animal type dominates the market?

Cattle held the largest market share in 2025, supported by extensive vaccination requirements across dairy and beef production.

9. Who are the major companies in the market?

Major companies include Zoetis, Merck Animal Health, Boehringer Ingelheim, Elanco, Ceva Santé Animale, HIPRA, Virbac, and Indian Immunologicals Limited.

10. What are the key factors driving market growth?

Key growth factors include rising animal disease incidence, preventive vaccination programs, expanding pet ownership, livestock production, and the development of advanced biological therapies.

Related Reports

1. Topical Flea Treatments Market

About IG Transformation Partners

IG Transformation Partners (IGTPS) is a global market research, advisory, and IT services company helping organizations turn data into strategic advantage. We provide syndicated market research reports, customized research, market intelligence, business advisory, and technology solutions to support informed decision-making, identify growth opportunities, and drive sustainable business outcomes.

Contact Us

For market research, customized research, advisory services, or business inquiries, connect with our team.

Email: info@igtps.com

Website: https://www.igtps.com